Work

Common Mechanistic Pathways in Cancer and Heart Failure. A Scientific Roadmap on Behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Year: 2020
Type: article
Abstract: The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre-clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time.
Institutions: University Medical Center Groningen, Inserm, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris Cardiovascular Research Center, Federico II University Hospital, University of Naples Federico II, Ospedale Policlinico San Martino, University of Genoa, Berlin-Brandenburger Centrum für Regenerative Therapien, German Centre for Cardiovascular Research, Charité – Universitätsmedizin Berlin, Medizinische Hochschule Hannover, Universitätsklinikum Würzburg, Vilnius University, Carol Davila University of Medicine and Pharmacy, Innate Pharma (France), University Medical Center Hamburg-Eppendorf, National and Kapodistrian University of Athens, University of Cyprus, University General Hospital Attikon, Universitat Autònoma de Barcelona, Instituto de Salud Carlos III, Centro de Investigación en Red en Enfermedades Cardiovasculares, Centro de Investigación Biomédica en Red, Hospital Universitari Germans Trias i Pujol, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, Wroclaw Medical University, Albert Einstein College of Medicine, University of Minnesota, Royal Marsden NHS Foundation Trust, German Cancer Research Center, Washington University in St. Louis, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Christian-Albrechts-Universität zu Kiel, University of Geneva, University of Parma, Guglielmo da Saliceto Hospital, University Hospital Hradec Králové, Medical University of Graz, University Hospital Zurich, Maine Medical Center, Maine Medical Center Research Institute, Serbian Academy of Sciences and Arts, University of Belgrade, University of Bern, University Hospital of Bern, Utrecht University, University Medical Center Utrecht, Universitätsmedizin Göttingen, University of Göttingen, Maastricht University, KU Leuven, Royal Brompton Hospital, Imperial College London
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,300
OpenAlex ID: W3093860253
FWCI: 13.76
Cites: 144
Cited by: 191
Related to: 10